Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc ONCY


Primary Symbol: T.ONC

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by CarbonWarrioron Nov 23, 2022 10:58am
185 Views
Post# 35121863

RE:RE:RE:RE:Merck KGaA/Pfizer's 90 day exclusivity period in effect now

RE:RE:RE:RE:Merck KGaA/Pfizer's 90 day exclusivity period in effect nowHey Noteable, 

Why do you say that the 90days period is in effect?


To my knowledge there is no PR about Bracelet-1 being completed. 
Initially they had hope for Q4 2022. 
Enrollement was compteted somewhere in August, 2022..
So somewhere Dec/Jan the last patient would have completed 16 weeks
Give them a couple weeks do compile that's Feb (start of the 90 days) 
A Press release must be done for the 90 days count down... it very material information...

ASCO in June 2023 is the date they are aiming for as a major release.
SP will go nutz from here until ASCO June 2023.
<< Previous
Bullboard Posts
Next >>